Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, FDA
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for those manufacturers to make safely.
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
Novo Nordisk asks FDA to ban cheap copies of Wegovy, Ozempic, CNBC reports
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks,
Novo seeks to block compounders' Ozempic copies
Novo Nordisk is pushing the FDA to block compounders from making copies of its Ozempic and Wegovy, saying the weight-loss treatments are too complex to safely replicate. Why it matters: It's the latest twist in the battle between pharma giants and compounders over the law that allows copies of patent-protected drugs amid shortages.
Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs
Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight loss and diabetes medications.
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.
Drugmaker wants an end to Ozempic copies
FDA recalls thousands of antidepressant bottles due to cancer-causing chemical{beacon} Health Care Health Care The Big Story Novo
The Cut on MSN
6h
Ozempic Influencers’ Time Might Be Up
She’s there to field questions from viewers who are considering — or have recently begun — prescription weight-loss ...
22h
on MSN
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
BioSpace
4h
GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...
Healthline
2d
How Ozempic, GLP-1 Weight Loss Drugs Affect the Brain to Curb Substance Misuse
A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like ...
FiercePharma
1d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
In the middle is the
FDA
trying to referee the high-stakes and increasingly ... from manufacturing copycat versions of its ...
Rolling Out
4d
Understanding Ozempic: Weight loss, side effects and hair loss concerns
While Ozempic’s weight loss benefits are widely touted, the conversation is increasingly shifting toward its side effects.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Novo Nordisk
Wegovy
Food and Drug Administration
Feedback